By Monica Heger

The Mayo Clinic is developing an 18-gene colon cancer panel for the Illumina Genome Analyzer with the goal of offering a single test that will be able to diagnose different subtypes of hereditary colon cancer.

The test, which the researchers are planning to launch next year, will use Agilent's SureSelect in-solution custom capture technology and will be offered to physicians as a lab-developed test with a turnaround time of between four to six weeks.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.